Lipid Modifying Therapy (LMT)

DRUG3 trials

Sponsors

Sanofi

Conditions

HypercholesterolaemiaHypercholesterolemia

Phase 3

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

CompletedNCT01617655

SanofiHypercholesterolaemia

Start: 2012-06-30End: 2015-01-31Updated: 2016-10-04

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

CompletedNCT01623115

SanofiHypercholesterolemia

Start: 2012-07-31End: 2014-12-31Updated: 2016-02-08

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

CompletedNCT01644188

SanofiHypercholesterolemia

Start: 2012-08-31End: 2015-07-31Updated: 2016-08-04

Related Papers

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

2017-09-0438 citations

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Journal of the American College of Cardiology2017-01-30193 citations

Reductions in Atherogenic Lipids and Major Cardiovascular Events

Circulation2016-10-25128 citations

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.

2016-10-01167 citations

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

European Heart Journal2015-09-01531 citations

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

European Heart Journal2015-02-16394 citations

ODYSSEY FH I and FH II: Alirocumab Significantly Improves Cholesterol Levels in Patients with HeFH

MD Conference Express2014-10-01

ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk

MD Conference Express2014-10-01

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

2014-09-2042 citations

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

2014-06-0172 citations